Skip to content
All about technology. — All about artificial intelligence.

FDA appoints top AI officer to expedite scientific evaluations

FDA to Implement AI for Streamlining Repetitive Tasks: Commissioner Martin Makary Announces AI Deployment Across All FDA Centers

,   and  Administrator
3 min read
FDA designates a new artificial intelligence executive to expedite scientific deliberations
FDA designates a new artificial intelligence executive to expedite scientific deliberations

FDA appoints top AI officer to expedite scientific evaluations

The Food and Drug Administration (FDA) is set to roll out a generative AI platform, marking a significant stride in its modernization strategy. This move follows the successful completion of a pilot AI project, as announced by FDA Commissioner Dr. Martin Makary.

Jeremy Walsh, the newly appointed Chief AI Officer at the FDA, plays a pivotal role in this initiative. Walsh, who previously worked as chief technologist at consulting firm Booz Allen Hamilton for 14 years, is spearheading the agency’s AI initiatives, including the development and implementation of Elsa—a generative AI tool designed to enhance internal efficiency for scientific review and regulatory work.

Walsh's leadership extends beyond Elsa's development. He chairs two cross-agency AI councils, one focused on internal AI use within the FDA, including staff training and piloting programs, and the other on policy development for AI in FDA-regulated products. This dual leadership role positions Walsh at the centre of harmonizing AI deployment and regulatory oversight, ensuring consistency across FDA’s divisions while managing risks associated with AI implementation.

Walsh emphasizes the importance of maintaining human oversight, combating challenges like AI hallucination (generation of inaccurate information), and ensuring validation, transparency, and security safeguards in AI tools used by the agency. For instance, Elsa operates in a secured GovCloud environment and is not internet-connected to protect sensitive data, although it faces limitations in real-time information access.

The rollout of the AI platform will be coordinated by Walsh and Sridhar Mantha, who was previously leading the Office of Business Informatics in the FDA's Center for Drug Evaluation and Research. More details on the initiative will be released in June, according to the statement.

The launch of the common AI system across FDA centers aims to speed scientific reviews and accelerate the review time for new therapies. However, the potential cost of the AI platform rollout remains undisclosed. The White House's Office of Management and Budget has directed agencies to name a chief AI officer and to develop and retain AI talent, but the statement did not specify its role in the AI platform rollout.

Despite the Trump administration revoking a Biden administration plan for regulating AI in healthcare, the FDA's AI initiative continues to move forward. President Donald Trump's policies' potential impact on the initiative remains unclear from the available information.

In conclusion, the FDA's AI platform rollout represents a significant step towards modernizing the agency's operations, enhancing decision-making efficiency in healthcare services, and accelerating the review process for new therapies. The initiative, under the leadership of Jeremy Walsh, is expected to free up FDA scientists and subject matter experts to focus on more complex tasks, contributing to the overall efficiency of the agency.

  1. Jeremy Walsh, as the Chief AI Officer at the FDA, is leading the agency's AI initiatives, including the development and implementation of Elsa, a generative AI tool for internal efficiency.
  2. Walsh chairs two cross-agency AI councils, focusing on internal AI use within the FDA, staff training, and piloting programs, as well as policy development for AI in FDA-regulated products.
  3. The Food and Drug Administration (FDA) is set to roll out a common AI system across its centers, aiming to speed scientific reviews and accelerate the review time for new therapies.
  4. The launch of the AI platform will be coordinated by Walsh and Sridhar Mantha, with more details to be released in June.
  5. Despite the Trump administration's revocation of a Biden administration plan for regulating AI in healthcare, the FDA's AI initiative continues to move forward.
  6. The White House's Office of Management and Budget has directed agencies to name a chief AI officer and to develop and retain AI talent, but its role in the AI platform rollout remains undisclosed.
  7. The FDA's AI platform rollout is a significant step towards modernizing the agency's operations, enhancing decision-making efficiency in healthcare services, and accelerating the review process for new therapies.

Read also:

    Related

    Latest